Mattioli A V, Bettelli G, Mattioli G
Cattedra di Malattie dell'Apparato Cardiovascolare, Università degli Studi, Modena.
Cardiologia. 1991 Mar;36(3):223-7.
We studied 78 consecutive patients with dilatative cardiomyopathy who were in our hospital because of heart failure. We wanted to evaluate which parameters could be useful in identifying patients who could be treated with betablockers. All patients were hemodynamically well balanced. They were treated with effective dosage of digoxin and diuretics. We evaluated the following hemodynamic parameters: heart rate, mean arterial pressure, mean pulmonary arterial pressure (MPAP), right atrial pressure, pulmonary wedge pressure, cardiac output, cardiac index, systemic vascular resistance, pulmonary vascular resistance, and also the neurohumoral parameters: VO2, max exercise duration, plasmatic norepinephrine levels (NE) and plasmatic renin activity (PRA). Then all patients were treated with atenolol 25 mg/die followed by 50 mg/die. In the overall population, 37 patients well tolerated the therapy with betablocker (Group A); 41 patients did not tolerate the therapy (Group B). Between the 2 groups we only found a significant difference in MPAP 31 +/- 20 vs 51 +/- 31 mmHg (p = 0.02), NE 781 +/- 467 vs 1551 +/- 1249 pg/ml (p = 0.01), PRA 1.8 +/- 2.9 vs 5.6 +/- 4.5 ng/ml/h (p = 0.02). On the basis of our results we hypothesize that patients with high neurohumoral activation do not tolerate betablocker treatment.
我们研究了我院78例因心力衰竭而入院的扩张型心肌病患者。我们想评估哪些参数有助于识别可使用β受体阻滞剂治疗的患者。所有患者血流动力学均保持良好平衡。他们接受了有效剂量的地高辛和利尿剂治疗。我们评估了以下血流动力学参数:心率、平均动脉压、平均肺动脉压(MPAP)、右心房压、肺楔压、心输出量、心脏指数、体循环血管阻力、肺血管阻力,以及神经体液参数:VO2、最大运动持续时间、血浆去甲肾上腺素水平(NE)和血浆肾素活性(PRA)。然后所有患者接受阿替洛尔治疗,初始剂量为25mg/天,随后增至50mg/天。在总体人群中,37例患者对β受体阻滞剂治疗耐受性良好(A组);41例患者不耐受该治疗(B组)。两组之间我们仅发现MPAP有显著差异,分别为31±20 mmHg和51±31 mmHg(p = 0.02),NE分别为781±467 pg/ml和1551±1249 pg/ml(p = 0.01),PRA分别为1.8±2.9 ng/ml/h和5.6±4.5 ng/ml/h(p = 0.02)。基于我们的研究结果,我们推测神经体液激活程度高的患者不耐受β受体阻滞剂治疗。